Forum

CTX.TO - Crescita Therapeutics

Autre nouvelle intéressante qui pourrait avoir un impact éventuel sur CTX: Knight Therapeutics to Acquire Grupo Biotoscana, Establishing a Latin American Growth Platform

Knight est un actionnaire importante de Crescita et ce n’est pas un secret que Knight avait commencé à vendre sa position au cours des derniers mois. L’objectif initial de Knight était d’obtenir les droits sur Pliaglis au Canada, ce qui n’a pas porté fruit. Maintenant que Knight possède une plateforme de distribution en Amérique Latine, peut-être que la possibilité de négocier une licence pour Pliaglis dans certains territoires de la région devient intéressante.

Si c’était le cas:

  1. Crescita pourrait trouver un partenaire intéressant pour commercialiser dans de nouveaux pays.

  2. Il y aurait beaucoup moins de pression sur le titre si Knight cessait de vendre ses actions. On pourrait assister à une réévaluation à la hausse assez rapide du titre.

Ce ne sont que mes propres suppositions. Je n’ai pas confirmé aucune information avec le management, mais je vous laisserai savoir si j’en apprend davantage éventuellement.

3 J'aimes

En effet, l’Amérique latine représente un beau potentiel pour Crescita , je crois que pour le Canada l’ entreprise va s’appuyer sur son effectif actuel. Concernant knight , ont-ils continuer à vendre depuis le 8 aout 2019 où leur position était à 1,9 millions en dessous du seuil de 10%.

À ma connaissance Knight n’est plus initié et ne doit plus divulguer ses transactions.

En effet, c’est possible qu’ils continuent à vendre mais ce serait surprenant à moins de $1.

Crescita’s Pliaglis enhanced formulation okayed by FDA

1 J'aime

On October 25th, I spoke with Executive Chairman Dan Chicoine. I’ve summarized our conversation in Part 2 of my analysis. I was satisfied with the answers he provided.
I also conducted some very basic research in my hometown regarding Laboiratoire Dr. Renaud and Pro-Derm. I did this to try and gather a bit of customer opinion on their skincare brands and familiarize myself with their products.

I like where the company is heading. Their current operations require very little if any further investment. How they deploy their cash will be critical to the companies growth.

4 J'aimes

Crescita Reports 2019 Third Quarter Results

2 J'aimes

A mon avis ce sont de bons résultats avec un bon ebitda ajusté de près de 1 M$ et un encaisse de 13 M$ , en plus la compagnie va recevoir un autre 750K$ de Taro pour le FDA approval.

1 J'aime
4 J'aimes
1 J'aime

Crescita Awarded Cannabis Research License from Health Canada

2 J'aimes

Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis

Je ne crois pas que le marché attribue beaucoup de valeur à ce produit. Cela dit, une autre étape importante vient d’être franchie et on s’approche du moment où cela pourrait créer de la valeur pour les actionnaires de Crescita.

2 J'aimes

Semble-t-il que non, l’action n’a pas bougé et pourtant ?

2 J'aimes

Est-ce que quelqu’un sait si il fait référence au brevet de PLIAGLIS qui expire en 2020? Ou un autre changement? Je viens juste de commencer à suivre cette compagnie. merci.
page 30 du MD&A Q4 2019.
« In addition, the Company was informed by its U.S. partner, Taro, of certain restrictive amendments to managed care in the U.S. which may have an adverse impact on Pliaglis sales in the future. Although the impact cannot be quantified and its extent is unknown at this time, the Company, along with its partner, will be closely monitoring sales in the U.S. »

Résultats trimestriels décevants publiés aujourd’hui et management peu actif pour valoriser leur actifs . I am out

I plan on emailing Linda Kisa at Crescita tomorrow with some questions. That paragraph is one of them. I’m not finding anything on Google about what a restrictive amendment is.

Linda is their IR person and also an accountant. Very knowledgeable.
lkisa@crescitatx.com

1 J'aime

Je ne penserais pas que ce soit lié au brevet qui expire. Une nouvelle formulation de Pliaglis (avec un nouveau brevet valide jusqu’en 2031 si je ne me trompe pas) est déjà approuvée par le FDA.

Cela dit, comme plusieurs autres investisseurs, je ne sais pas de quoi il s’agit lorsque la compagnie mentionne ‹ ‹ adendments to managed care in the US › ›. J’ai envoyé un courriel à Linda hier, mais pas de réponse encore.

Voici la réponse que j’ai reçu:

In response to your question re Pliaglis U.S.,I can direct you to what we know. Here are some articles that talk about the amendments to drug reimbursement plans where there are limits established on reimbursement of certain products by Express Scripts and CVS Caremark, two of the large pharmacy benefit managers in the U.S. Pliaglis is included under the product name Lidocaine/Tetracaine.

We don’t know yet how this will be enforced exactly and how these limits will affect the sales of Pliaglis. All we know is that it may have an impact. We are working with Taro and, of course, they are trying to mitigate any potential negative impact on sales. Although we do not know all the details and it is too early to determine the potential impact on sales, we believe that it is important to be transparent with our investors.

https://www.frierlevitt.com/articles/pharmacylaw/pharmacy-alert-cvs-caremark-releases-dispensing-limitations-to-be-effective-january-2020/

Crescita Therapeutics Announces Measures in Response to COVID-19 Virus

2020-03-24 19:23 ET - News Release

LAVAL, QC, March 24, 2020 /PRNewswire/ - Crescita Therapeutics Inc. ( TSX: CTX) ( OTC US: CRRTF ) (« Crescita » or the « Company »), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (« R&D ») and manufacturing capabilities, today announced measures it is taking in response to the novel coronavirus pandemic (« COVID-19 »).

In accordance with the government-mandated shut-down of all non-essential businesses announced by Québec Premier François Legault yesterday, the Company will be temporarily closing its office and production facility in Laval, Québec, effective today at midnight until at least April 13, 2020. The facility closure will regretfully result in temporary layoffs affecting most production and office personnel. Certain employees deemed critical to maintaining basic services during the shut-down, including customer service, will be working remotely with reduced hours. Product distribution through the Company’s third-party logistics provider will remain operational with reduced capacity.

Business Impact to Date

Most of the Company’s Canadian clients in the aesthetic and medical aesthetic markets have temporarily closed resulting in substantially decreased Canadian product sales. The Company’s international business with various affected countries such as Malaysia, South Korea and China has also decreased. The Company anticipates that royalties from international sales of its products will be adversely affected by lower demand and may also be affected by border restrictions.

The Company is in the process of implementing various initiatives in order to conserve cash and help maintain its financial flexibility through the uncertainties and economic pressures posed by the pandemic. The members of the executive team, including the CEO and CFO, as well as members of the Company’s Board of Directors have agreed to temporary base salary or fee reductions ranging between 25% and 40%. In addition, effective March 24, 2020, the Company terminated its Automatic Share Purchase Plan (« ASPP ») which was launched on June 28, 2019 in connection with the Company’s current normal course issuer bid (« NCIB »). The current NCIB remains in effect on the same terms and conditions as previously disclosed. As of December 31, 2019, the Company had cash and cash equivalents of $9.3 million.

The Company is closely monitoring developments and will continue to provide updates as the COVID-19 situation evolves.